Am I a Candidate for Gene Therapy for My Inherited Retinal Disease?
Gene Therapy for Inherited Retinal Disease at a Glance
Right now, one gene answers this question. A retinal gene therapy, voretigene neparvovec, was approved in the United States in 2017 and in the European Union in 2018, and it treats only inherited retinal disease caused by changes in a gene called RPE651. To be treated you need a confirmed change in both copies of RPE65, and you need enough living retinal cells left for the treatment to work on2.
That is a narrow door. Nearly 300 genes can cause inherited retinal disease1, so most people reading this will not have the one treatable gene. Knowing which gene you have still matters.
A clinical label like retinitis pigmentosa or Leber congenital amaurosis describes what your retina looks like, not which gene is behind it. Genetic testing is the only way to identify the causative gene change1, and the approved therapy is licensed only for people with a confirmed change in both copies of RPE652.
Without that result, nobody can tell you whether you are a candidate. With it, you get a real answer either way, plus access to trials and to family testing.
This page explains who fits the current criteria, what the consultation and surgery involve, and what the results have looked like. It cannot tell you whether your own eyes qualify. That needs your genetic report, scans of your retina, and an exam by a retina specialist who does this work.
If you are already carrying a genetic report, bring it to that appointment. It is the single document that moves the conversation forward fastest.
What Retinal Gene Therapy Actually Is
Your retina runs on proteins built from instructions in your genes. In RPE65 disease, a supporting layer of the retina cannot make a protein needed to recycle light-sensing chemicals, so the retina works poorly from early childhood and slowly deteriorates.
Gene therapy supplies a working copy of that instruction. The carrier is a modified virus that cannot copy itself (clinical: a live, non-replicating adeno-associated virus type 2), altered to carry the human RPE65 gene, and the recommended dose for each eye is 1.5 x 10^11 vector genomes, a count of the gene-carrying copies delivered, given by injection under the retina in a total volume of 0.3 mL2. The cells then read the delivered gene and make the missing protein.
The product is voretigene neparvovec, sold as Luxturna. It is licensed for patients with confirmed changes in both copies of RPE65 who have viable retinal cells, and it is given only by injection under the retina2. It is a one-time treatment for each eye rather than an ongoing medicine.
The approval covers one gene: retinal dystrophy caused by confirmed changes in both copies of RPE652. Because the licensed indication is that narrow, the candidacy question so often comes down to which gene you have.
The field is active well beyond RPE65. Trials are under way for other inherited retinal conditions, including achromatopsia, X-linked retinoschisis and Stargardt disease1. Some target a single gene, others aim to work regardless of the gene involved.
An investigational treatment is not the same as an available one, and trials carry their own risks and time commitments. A confirmed genetic diagnosis is usually required to enroll, which is another reason testing comes first.
Who Is a Good Candidate for RPE65 Gene Therapy
Candidacy rests on three findings rather than on how poor your vision feels. You need changes in both copies of RPE65 confirmed by genetic testing and enough surviving retinal cells as judged by your treating doctors2, and treatment is not recommended before 12 months of age3.
All three are checked with objective tests. That can feel out of your hands, but it also means the answer does not depend on how well you describe your symptoms.
The pivotal trial enrolled people aged 3 years and older4, and a specialist center has reported treating children as young as 15 months5. There is no upper age limit in the license.
What changes with age is not eligibility but how much retina is left. Earlier treatment generally means more surviving cells to work with, which is why teams move once the genetic result is in rather than waiting for vision to worsen.
The therapy supplies instructions to cells that are still alive. If those cells are gone, delivering the gene changes nothing. The license therefore requires viable retinal cells, judged by the treating physicians2.
In practice this is assessed with retinal scans and examination, not a single number. Two people with the same genetic result and diagnosis label can get different answers.
Most people with inherited retinal disease fall into this group, and there is no approved gene therapy for them yet. That is disappointing news, not a dead end. A confirmed genetic result opens the door to trials, to accurate information about how your condition tends to progress, and to testing for relatives.
Low-vision rehabilitation, mobility training and workplace support are available now and are not a consolation prize. They often make a bigger day-to-day difference than people expect.
Who Should Wait or Consider Another Path
The most common reason a genetically eligible person is turned down is that scans show too few surviving cells in the target area. Viable retinal cells are a condition of the licensed indication, judged by the treating physicians2.
If you are told this, ask what was seen and whether a second opinion at another center is reasonable. Teams differ a little in where they draw the line.
This is retinal surgery, so the usual surgical timing rules apply. Active eye infection or inflammation, a recent eye injury, or an unstable general medical problem are reasons to delay until things settle. The prescribing information lists no absolute contraindications, but it does require a course of oral steroid around each surgery2, so any condition that makes short-term steroids risky needs planning with your other doctors.
Postponing for a few weeks to sort these out is normal and does not usually change the long-term picture.
Use in infants under 12 months of age is not recommended, because retinal cells are still actively dividing at that stage and the delivered gene may be diluted or lost3. This is a timing rule, not a permanent exclusion.
For families of a very young baby with a confirmed RPE65 result, the useful step is to get established with an inherited retinal disease center early so that scans, counseling and insurance approval are already in place when the age window opens.
What Happens at the Consultation
A candidacy visit is longer than a routine eye appointment. Expect vision measurement in ordinary and dim light, visual field testing, detailed retinal imaging to count what is left of the light-sensing layers, and a review of your genetic report by someone who reads these reports regularly.
Some centers also use a mobility course in graded lighting. That kind of test was the main measure in the pivotal trial, because it captures functional vision rather than letters on a chart4.
If you have never had testing, ask your eye doctor to arrange it rather than buying a consumer kit. In the United States, the My Retina Tracker Program provides genetic testing and genetic counseling at no cost to patients who have a clinical diagnosis of an inherited retinal disease and an eye specialist enrolled as an ordering provider, with testing at PreventionGenetics and counseling through InformedDNA6.
Targeted testing is also offered to blood relatives of someone with a positive result6, which often matters more to families than they expect.
The price is high and worth discussing early. At launch in 2018 the manufacturer set the price at $425,000 per eye, or $850,000 for both eyes7. What you actually pay depends entirely on your coverage, so the number to ask about is your share, not the list price.
Treatment happens at a small number of designated centers. One United States safety study drew its patients from 10 such centers8. Ask the center's coordinator to start insurance authorization at your first visit, since that step usually takes the longest.
How the Treatment Is Actually Given
The gene therapy is placed under the retina in an operating room, not injected in a clinic room. The surgeon first removes the gel inside the eye, then raises a small blister of fluid containing the therapy under the retina at a chosen spot. Each eye receives 0.3 mL, and the second eye is treated no fewer than 6 days after the first2.
Most people have both eyes treated within a couple of weeks, under general anesthesia for children and often for adults too.
The label specifies oral prednisone at 1 mg per kg per day, up to 40 mg a day, beginning 3 days before treatment of each eye and continuing for 7 days, followed by a taper over the next 10 days2. The purpose is to calm the immune response to the carrier virus.
Take it exactly as written and do not adjust it yourself. If you have diabetes, a stomach ulcer history or a mood disorder, flag it before surgery so the team can plan monitoring.
The fluid blister puts the carrier virus directly against the supporting cell layer that needs the gene. The blister settles within about a day, and the retina reattaches on its own.
The delivered gene works inside those cells without changing the DNA your children would inherit. It is a supply of instructions to one tissue, which is also why the effect is limited to the area the surgeon covers.
Recovery and the First Weeks Afterwards
Expect a red, gritty, light-sensitive eye for several days, drops on a schedule, and a review appointment within a day or two. Most people feel well enough for quiet activity almost immediately, though the treated eye is blurry at first while it settles.
Children usually bounce back faster than their parents expect. The steroid course, not the eye itself, is often the part families find hardest.
This one catches people out, so plan travel before surgery. A gas bubble may be left in the eye, and while it is present you must avoid air travel, travel to high elevations and scuba diving, because the bubble can expand and raise the pressure inside the eye; this can take a week or more to clear3.
Your surgeon will tell you when the bubble has gone. Until then, drive or take the train rather than booking a flight home.
Improvement in dim-light vision is typically noticed over weeks rather than immediately, and it shows up more in navigating a dim room than in reading smaller print. In pooled post-approval data the largest gain was in light sensitivity, with only a small average gain in visual acuity9.
Settle expectations before surgery. Families expecting sharper reading vision are more likely to feel let down by a result that is genuinely useful.
Risks, Realistic Results, and What Is Still Unknown
In the phase 3 trial, 31 people were randomly assigned and 20 treated participants were compared with 9 controls; after 1 year the treated group improved by 1.8 light levels on a mobility course versus 0.2 in controls, and 13 of the 20 treated participants, but none of the controls, could complete the course at the dimmest light tested4.
That is a real change in what people can do in low light. It is also an average from a small group, describing that trial rather than what will happen to any one person.
A meta-analysis of post-approval studies reported a pooled improvement of 2.2 log units in light sensitivity and a small improvement of 0.08 logMAR in visual acuity9. A United States observational study of 87 patients followed for a median of 3.7 years reported that improvements in acuity and light sensitivity were still present at 3 years8.
Longer follow-up is still accumulating. Nobody can yet tell you with confidence how the benefit looks 15 or 20 years out.
One finding emerged only after the therapy was in wider use. Chorioretinal atrophy, meaning thinned patches of the retina and the layer beneath it, was not seen in the pivotal trials but was reported at a pooled rate of about 30 of every 100 treated people afterwards, and its clinical significance is still uncertain9.
A United States multicenter safety study of 87 treated patients reported chorioretinal atrophy in 24 of those 87, about 28 of every 100, typically within the first year, graded mild in about 80 of every 100 of the affected patients, with visual acuity and light sensitivity comparable in eyes with and without the atrophy8. Expert consensus reports that in most published series the atrophy does not appear to change visual outcomes, while noting that longer follow-up is needed and that regular imaging should track it10.
The operation carries the risks any retinal surgery carries. Labeled warnings include infection inside the eye, permanent decline in vision, retinal tears and macular holes, raised eye pressure, and cataract development or progression; among the 41 people (81 treated eyes) in the label's safety group, eye redness was reported in 9 of the 41 people, cataract in 8 of the 41, raised eye pressure in 6 of the 41 and a retinal tear in 4 of the 413.
Most of these are managed successfully when caught early, which is the whole reason for the close follow-up schedule. Permanent vision loss is on the list because it has happened, not because it is expected.
When to Contact Your Retina Team
After any eye surgery, some symptoms need same-day attention rather than a wait. Call your surgeon's office immediately, or use an emergency service if the office is closed, if you notice:
- Increasing eye pain that pain relief does not settle
- A rapid drop in vision, or a curtain or shadow across your vision
- A sudden shower of new floaters or persistent flashing lights
- Growing redness with discharge, especially with fever in a child
Infection inside the eye and retinal tears are labeled risks of this treatment3. Both are treatable when handled quickly, which is exactly why the threshold for calling should be low.
Between visits, report any new blank patch in your vision, new distortion of straight lines, or a step down in how you manage in dim light. Also report any problem while you are on the steroid course, such as high blood sugar readings, stomach pain or marked mood change.
None of these means something has gone wrong. They are the things your team would rather see early than at the next scheduled visit.
Follow-up is closest in the first weeks and then settles into long-term monitoring. Expert consensus recommends regular follow-up visits combining retinal imaging with vision measures, so that both benefit and any atrophy are tracked over time10.
Keep these appointments even when your vision feels stable. They are how a treatable complication gets caught, and how the long-term evidence still gets built.
Common Questions About Gene Therapy Candidacy
Ask your eye doctor to order inherited retinal disease genetic testing rather than using a consumer ancestry kit. In the United States, the My Retina Tracker Program covers testing and genetic counseling at no cost for people with a clinical diagnosis of an inherited retinal disease whose eye specialist is an enrolled ordering provider6. Results usually take some weeks. Ask for a copy of the full report, since you will need it for referrals, trials and any future treatment discussion.
Not as an approved treatment. Voretigene neparvovec is licensed only for retinal dystrophy caused by confirmed changes in both copies of RPE652. Trials are running for several other conditions, including achromatopsia, X-linked retinoschisis and Stargardt disease1. Ask your specialist whether a trial fits your gene, your age and your current vision, and register with a patient registry so that you hear when new studies open.
No, and it is important to hear that before deciding. The treatment aims to improve what your remaining retinal cells can do, especially in dim light. Pooled post-approval data show a substantial gain in light sensitivity and only a small average gain in visual acuity9. People commonly describe moving around a dim room more confidently. Reading fine print is usually not where the gain shows up.
Longer than a short-term treatment, but the full picture is still being written. A United States observational study of 87 patients found gains in visual acuity and light sensitivity still present at 3 years, with a median follow-up of 3.7 years8. Expert consensus notes that longer follow-up is needed to know whether benefit is maintained10. Anyone who offers you a confident 20-year figure is going beyond the evidence.
There is no upper age limit in the licensed indication. What the license requires is confirmed changes in both copies of RPE65 and viable retinal cells2. In practice, adults who have retained enough retinal structure can be considered, and adults have been treated. The honest limiting factor is how much light-sensing tissue remains, which is measured on scans rather than estimated from your age.
Often yes, if the genetic result matches. Use under 12 months of age is not recommended, because dividing retinal cells may dilute the delivered gene3. A specialist pediatric center has reported treating children as young as 15 months, with visual improvement confirmed on objective testing, alongside transient inflammation in 5 of 14 children and localized atrophy in 6 of 145. Ask for referral to a designated center early.
More Questions About Cost, Risk, and Next Steps
The list price is among the highest in medicine. At launch in 2018 it was set at $425,000 per eye, or $850,000 for both eyes7. What you actually pay depends entirely on your coverage. Ask the treatment center's coordinator to begin authorization at your first visit and to tell you in writing what your expected share would be before you commit.
Discuss them, but weigh them properly. Thinned patches of retina were reported at a pooled rate of about 30 of every 100 treated people after approval, and the clinical significance is still uncertain9. Expert consensus reports that in most series it does not appear to affect visual outcomes, while calling for longer follow-up and regular imaging10. It is a genuine reason for close monitoring rather than an automatic reason to decline.
Not straight away. If a gas bubble is left in the eye you must avoid air travel, high elevations and scuba diving until it clears, which can take a week or more, because the bubble can expand and raise the pressure inside the eye3. Plan ground transport, and if you have traveled a long way, budget for staying near the center until your surgeon confirms the bubble has gone.
Three things are worth doing. Get and keep a full genetic report, join an inherited retinal disease registry so that trial invitations can reach you, and take up low-vision rehabilitation now rather than later. Genetic testing programs that connect results to a registry exist at no cost to United States patients with a clinical diagnosis6. Ask your specialist to review your options again if your circumstances change.
- Has my causative gene been confirmed, and can I have a copy of the report?
- Do my scans show enough living retinal cells for treatment to be considered?
- Which treatment center would you refer me to, and how long is the wait?
- What realistic change in my day-to-day vision should I expect?
- What is the plan for the steroid course given my other health conditions?
- How will you monitor me for thinning of the retina afterwards?
- How long must I avoid flying, and when will you confirm that?
- If I am not eligible, which trials or registries should I look into?
- peer-reviewed comprehensive review, PubMed Central (2026). Gene Therapy for Inherited Retinal Disease: Current Strategies, Personalized Medicine, and Future Implications, A Comprehensive Review.
- US prescribing information, DailyMed (Spark Therapeutics) (2024). LUXTURNA (voretigene neparvovec-rzyl) prescribing information.
- US prescribing information, DailyMed (Spark Therapeutics) (2024). LUXTURNA prescribing information, Warnings and Precautions and Adverse Reactions.
- The Lancet (open-label randomised controlled phase 3 trial, 2 US sites) (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
- JAMA Ophthalmology (retrospective single-center case series, 14 children, 27 eyes) (2026). Vision Outcomes in Children Treated With Voretigene Neparvovec for RPE65-Associated Retinopathy.
- Foundation Fighting Blindness (2025). Open Access Genetic Testing Program (My Retina Tracker Program).
- American Academy of Ophthalmology, professional news headline (2018). Spark unveils $850,000 price tag for Luxturna.
- Ophthalmology (prospective multicenter post-authorization observational safety study, 87 patients at 10 centers) (2026). Interim Results From a Multicenter Observational Safety Study of Patients Treated With Voretigene Neparvovec-rzyl in the United States.
- Survey of Ophthalmology (systematic review with random-effects meta-analysis) (2026). Post-approval outcomes of voretigene neparvovec (Luxturna) retinal gene therapy: A systematic review and meta-analysis.
- Ophthalmology Science (international expert consensus and literature review) (2026). Expert Consensus on Characteristics, Etiology, and Management of Chorioretinal Atrophy in Patients Treated with Voretigene Neparvovec.